Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

TTD Drug ID: DAP000366

Drug Information
NameMethysergide    
SynonymsNCGC00024027-04; D02357; EINECS 206-644-0; N-(1-(Hydroxymethyl)propyl)-1-methyl-dextro-(+)-lysergamide; 29987-97-1; Ergoline-8-beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-; C07199; Methysergidum [INN-Latin]; 9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8-carboxamide; Desril; CHEBI:238605; DB00247; Methysergid; 1-Methyl-D-lysergic acid butanolamide; Metisergido; Methysergidum; Lysergamide, N-(1-(hydroxymethyl)propyl)-1-methyl-, D-; Desernil; BPBio1_000486; Desernyl; Methysergide (USAN/INN); Metisergide [DCIT]; UNII-XZA9HY6Z98; 1-Methylmethylergonovine; 47478-64-8; Metisergide; CHEMBL1065; 156558-44-0; Ergoline-8beta-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-; Methysergide [USAN:INN:BAN]; Methyllysergic acid butanolamide; BRD-K35941380-001-01-7; Sansert; Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta(S))-; Biomol-NT_000155; 361-37-5; HSDB 3237; UML-491; methysergide; NCGC00024027-06; BRN 0765985; 1-Methyl-dextro-lysergic acid (+)-1-hydroxy-2-butylamide; 2016-33-3; LS-64361; Lopac0_000863; CID9681; Methylmethylergonovine; NCGC00024027-05; Deseryl; (+)-9,10-Didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethylergoline-8beta-carboxamide; AC1L1TKV; HMS2090P04; Metisergido [INN-Spanish]; 746-51-0; N-(alpha-(Hydroxymethyl)propyl)-1-methyl-dextro-lysergamide; (+)-N-(1-(Hydroxymethyl)propyl)-1-methyl-D-lysergamide; (8beta)-N-[(1S)-1-(hydroxymethyl)propyl]-1,6-dimethyl-9,10-didehydroergoline-8-carboxamide; UML 491; Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-1,6-dimethyl-, (8beta)-; Deseril; Dimethylergometrin; C21H27N3O2    
Trade NameSansert; Deseril    
CompanyNorvatis Phamaceuticals Corporation    
IndicationMigraine headachesApproved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
   
Therapeutic ClassVasoconstrictor Agents    
CAS NumberCAS 361-37-5
FormularC21H27N3O2    
PubChem Compound IDCID 9681.    
PubChem Substance IDSID 9408.    
SuperDrug ATC IDN02CA04;    
SuperDrug CAS ID000361375;    
Target5-hydroxytryptamine 2C receptorAntagonist[2][3][4][5]
Ref 1FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012516 To Reference
Ref 2Spinal serotonin receptor activation modulates the exercise ventilatory response with increased dead space in goats. Respir Physiol Neurobiol. 2008 May 31;161(3):230-8. Epub 2008 Feb 29. To Reference
Ref 3Intake of fermented soybean (natto) increased locomotor activity in mice. Biol Pharm Bull. 2007 Apr;30(4):845-6. To Reference
Ref 4Serotonergic mechanisms of the lateral parabrachial nucleus in renal and hormonal responses to isotonic blood volume expansion. Am J Physiol Regul Integr Comp Physiol. 2007 Mar;292(3):R1190-7. Epub 2006 Nov 30. To Reference
Ref 5p-Chloroamphetamine, a serotonin-releasing drug, elicited in rats a hyperglycemia mediated by the 5-HT1A and 5-HT2B/2C receptors. Eur J Pharmacol. 1998 Oct 23;359(2-3):185-90. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543